• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Janux Therapeutics Inc (NQ: JANX )

    48.12 -0.64 (-1.31%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Janux Therapeutics Inc

    < Previous 1 2 3 4 5 Next >
    Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and... 
    Via Benzinga
    Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
    From Janux Therapeutics
    Via Business Wire
    Janux Therapeutics: Q1 Earnings Insights
    Via Benzinga
    Janux Therapeutics's Return On Capital Employed Overview
    Via Benzinga
    Why Janux Therapeutics Shares Rose 33.1% This Week
    The clinical-stage biotech company just began its first clinical trial. 
    Via The Motley Fool
    Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results. 
    Via Benzinga
    Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    $27.5M Bet On Block? Check Out These 3 Stocks Insiders Are Buying
    Although U.S. stocks closed mixed on Monday, there were a few notable insider trades. 
    Via Benzinga
    Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
    From Janux Therapeutics
    Via Business Wire
    Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
    From Janux Therapeutics
    Via Business Wire
    Becton, Dickinson and Company, Applied Digital, POSCO And Other Big Stocks Moving Higher On Monday
    U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Janux Therapeutics' Stock Is Currently Undervalued, Analyst Highlights Prostate Cancer Candidate Potential
    Janux Therapeutics Inc (NASDAQ: JANX) announced interim Phase 1 clinical data for PSMA-TRACTr JANX007 in adult subjects with metastatic castration- 
    Via Benzinga
    Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
    From Janux Therapeutics
    Via Business Wire
    Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
    From Janux Therapeutics, Inc.
    Via Business Wire
    Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
    From Janux Therapeutics
    Via Business Wire
    Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
    From Janux Therapeutics
    Via Business Wire
    Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
    From Janux Therapeutics
    Via Business Wire
    Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
    From Janux Therapeutics
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2023
    Via Benzinga
    7 Biotech Stocks That Could Be the Next Big Thing
    Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. 
    Via InvestorPlace
    The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
    To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
    Via InvestorPlace
    Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
    From Janux Therapeutics
    Via Business Wire
    Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
    From Janux Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Why WestRock Company Are Trading Lower By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Gainers Versus Systems Inc. (NASDAQ: VS) surged 270% to $2.26 after the company announced it will partner with Resolve to bring generative AI and gamification to customer payments and credit... 
    Via Benzinga
    Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
    From Janux Therapeutics, Inc.
    Via Business Wire
    Janux Therapeutics to Present at Upcoming Investor Conferences in November
    From Janux Therapeutics, Inc.
    Via Business Wire
    7 Short-Squeeze Stocks for Bold Contrarians to Consider
    While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists. 
    Via InvestorPlace
    Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
    From Janux Therapeutics, Inc.
    Via Business Wire
    Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
    From Janux Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.